STOCK TITAN
  1. Home
  2. News
  3. ME

23andMe Holding Co. - ME STOCK NEWS

Welcome to our dedicated page for 23andMe Holding Co. news (Ticker: ME), a resource for investors and traders seeking the latest updates and insights on 23andMe Holding Co. stock.

23andMe Holding Co. Class A Common Stock (NASDAQ: ME) is a leading genetics-led consumer healthcare and biopharmaceutical company. Founded in 2006, 23andMe specializes in personal genome services through DNA analysis technologies and interactive web-based tools. The company’s core service allows individuals to gain deep insights into their genetic ancestry, health predispositions, and phenotypic traits.

23andMe's mission is to personalize healthcare by supporting meaningful discoveries through genetic research. The company's primary revenue comes from its Consumer and Research Services segment, which includes the sale of direct-to-consumer personal genome services (PGS). This involves shipping DNA collection kits to users, who can then access detailed reports on their genetic makeup through 23andMe’s platform.

The company also has a Therapeutics segment that focuses on leveraging genetic data to develop new treatments. Notably, 23andMe presented positive Phase 2 safety and efficacy data from their anti-CD200R1 antibody, 23ME-00610, at the 2024 American Society of Clinical Oncology (ASCO) Annual Meeting.

Despite its groundbreaking work, 23andMe recently faced a significant data breach, affecting approximately 7 million users. Hackers specifically targeted the genetic information of Jewish and Chinese customers, selling the data on the dark web. This incident has led to a class-action lawsuit and ongoing investigations.

In research, 23andMe has also made significant strides. For example, the company conducted the world's largest study on the LRRK2 G2019S variant linked to Parkinson’s disease, with support from The Michael J. Fox Foundation. Findings from this study revealed new insights into the variant's impact and its prevalence in various populations, including unexpected hotspots in Latin Caribbean communities.

23andMe continues to expand its offerings, providing reports that calculate genetic likelihood for conditions like bipolar disorder, anxiety, and depression for its 23andMe+ Premium members. These reports are based on polygenic risk scores (PRS) developed through the company’s extensive research database.

With a strong commitment to advancing personalized healthcare and continuous innovation in genetic research, 23andMe remains a significant player in the biotechnology and consumer healthcare sectors.

News

23andMe Data Breach - Hackers Targeted Jewish and Chinese Users Data

Rhea-AI Summary
23andMe (ME) faced a massive data breach in December 2023, affecting 7 million users, with hackers specifically targeting Jewish and Chinese customers. The personal genetic information, including heritage, names, and addresses, was compiled into lists and sold on the dark web. The breach poses a significant threat to customer safety, especially from potential government tracking. 23andMe has been accused of not informing compromised customers about the breach, leading to a class-action lawsuit.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-6.42%
Tags
none
-
News

23andMe Holding Co (NASDAQ:ME) Jewish and Chinese Users

Rhea-AI Summary
23andMe (NASDAQ:ME) faced a significant data breach in December 2023, impacting 7 million users. Hackers targeted Jewish and Chinese customers, selling their genetic information on the dark web. The company failed to disclose this critical detail to affected customers, putting their safety at risk. A class action lawsuit has been filed, highlighting the severity of the breach and the potential consequences for vulnerable individuals.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-7.97%
Tags
none
-
News

23andMe Holding Co (NASDAQ: ME) Jewish and Chinese Users

Rhea-AI Summary
23andMe (NASDAQ:ME) faced a massive data breach in December 2023, impacting 7 million users. Hackers targeted Jewish and Chinese customers, selling their genetic information on the dark web. The company failed to disclose this specific targeting, putting customers at risk. Lawsuits have been filed, alleging negligence and lack of transparency.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-4.03%
Tags
none
News

DATA BREACH- 23andMe Jewish & Chinese Consumers May be Affected

Rhea-AI Summary
23andMe (NASDAQ: ME) was hacked in December 2023, affecting approximately 7 million users of its genetic services website. Hackers targeted the personal genetic information of Jewish and Chinese customers, compiling data that was then sold on the dark web. The company concealed these details when notifying affected customers, posing a threat to the safety of the compromised customers. A class action lawsuit has been filed against 23andMe for failing to inform its customers about the extent of the breach and the specific targeting of Jewish and Chinese customers. The company's attempt to shift the blame to customers and the delayed reporting of the breach further complicate the situation.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-13.1%
Tags
none
-
News

23andMe Reports Third Quarter Fiscal 2024 Financial Results

Rhea-AI Summary
23andMe Holding Co. reported a decrease in total revenue for the third quarter of fiscal 2024 compared to the same period in the prior year. This was primarily driven by lower research services revenue due to the conclusion of the GSK collaboration exclusivity term and lower consumer services revenue. The company announced a new non-exclusive data license with GSK, introduced 23andMe Total Health™, and received FDA clearance for IND on a novel, dual-mechanism immuno-oncology asset. Additionally, 23andMe expanded its BRCA1/BRCA2 Genetic Health risk report and presented updated data for its Phase 1/2a study at the Society for Immunotherapy of Cancer conference. The company's net loss for the third quarter of fiscal 2024 increased compared to the same period in the prior year, and its adjusted EBITDA deficit also increased due to lower research services gross profit. 23andMe ended December 31, 2023, with cash and cash equivalents of $242 million and adjusted its full year guidance following the third quarter results.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-13.1%
Tags
earnings
-
News

DATA BREACH - 23andMe Jewish & Chinese Consumers May be Affected

Rhea-AI Summary
23andMe (NASDAQ:ME) was hacked in December 2023, affecting approximately 7 million users of its genetic services website. The hackers specifically targeted the personal genetic information of Jewish and Chinese customers and compiled that data into lists that were sold on the dark web. The company concealed these details when notifying affected customers. The lawsuit reveals that the hacker leaked a list of over 1 million Jewish customers expressly in retribution for the Israel-Hamas war, and a list of 350,000 Chinese customers upon request from a user with the alias 'Wuhan'. This disclosure threatens the safety of the customers. 23andMe has not informed the compromised customers that their personal genetic information was disclosed on the dark web, nor that they were specifically targeted. The PR also mentions the hacker's actions, prices for customer profiles, and 23andMe's attempt to shift the blame to customers.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
11.72%
Tags
none
News

23andMe Announces FDA Clearance of IND Application for its Dual Mechanism Antibody, 23ME-01473, Targeting ULBP6

Rhea-AI Summary
23andMe Holding Co. (Nasdaq: ME) has received FDA clearance for 23ME-01473 (‘1473), a natural killer (NK) cell activator intended to treat cancer. The drug targets ULBP6 to restore anti-tumor immunity through NK and T cells and is set to commence a Phase 1 clinical study in patients with solid tumors in the first half of 2024. '1473 has dual mechanisms of blocking the immunosuppressive effects of soluble ULBP6 and inducing Fc receptor-mediated killing of ULBP6-expressing cancer cells through enhanced effector function. This drug has the potential to address a major unmet need in cancer treatment by targeting patients who may have or may develop tumor resistance to checkpoint inhibitors.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-1.62%
Tags
clinical trial
-
News

23andMe Launches Month-Long Initiative to Amplify ARRAY’s “Seat16” Program for Acclaimed Film ORIGIN by Ava DuVernay

Rhea-AI Summary
23andMe Holding Co. (Nasdaq: ME) has announced a month-long initiative to support Ava DuVernay's new film ORIGIN and its groundbreaking Seat16 program. The program allows anyone to gift $16 or more to purchase an ORIGIN movie ticket for a young person who might not otherwise be able to afford it. 23andMe will donate 100 seats daily for 23 days to support the program, ensuring that 10,000 young people across the nation get to experience ORIGIN. The film, inspired by Pulitzer Prize-winning journalist Isabel Wilkerson's novel 'Caste: The Origin of Our Discontents,' explores the mystery of history, the wonders of romance, and a fight for our future, while investigating the global phenomenon of caste and its dark influence on society. With an expansive cast that includes Academy Award nominee Aunjanue Ellis-Taylor, Jon Bernthal, and Niecy Nash-Betts, the film aims to educate a new generation through its storytelling.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-1.62%
Tags
none
-
News

23andMe to Report FY2024 Third Quarter Financial Results

Rhea-AI Summary
23andMe Holding Co. (Nasdaq: ME) will report financial results for the FY2024 third quarter on February 7, 2024. The company aims to discuss its financial results and business progress through a webcast and Q&A platform for shareholders.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
6%
Tags
conferences earnings
News

DATA BREACH- 23andMe Holding Co Consumers May be Affected

Rhea-AI Summary
23andMe (NASDAQ: ME) experienced a significant data breach, affecting over 4 million users. The breach compromised personal information, including names, birth years, email addresses, genetic ancestry, potential relatives, and geolocation.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.28%
Tags
none

FAQ

What is the current stock price of 23andMe Holding Co. (ME)?

The current stock price of 23andMe Holding Co. (ME) is $3.11 as of November 22, 2024.

What is the market cap of 23andMe Holding Co. (ME)?

The market cap of 23andMe Holding Co. (ME) is approximately 82.8M.

What does 23andMe specialize in?

23andMe specializes in personal genome services, providing individuals with insights into their genetic ancestry, health predispositions, and phenotypic traits.

How does 23andMe generate its revenue?

The company primarily generates revenue through its Consumer and Research Services segment, which involves the sale of direct-to-consumer personal genome services.

What recent research has 23andMe conducted?

23andMe conducted the world's largest study on the LRRK2 G2019S variant linked to Parkinson’s disease, uncovering new insights and variant prevalence in various populations.

What was the recent data breach involving 23andMe?

In December 2023, 23andMe experienced a data breach affecting approximately 7 million users. Hackers targeted and sold the personal genetic information of Jewish and Chinese customers on the dark web.

What are 23andMe's key offerings for 23andMe+ Premium members?

23andMe+ Premium members have access to reports that calculate genetic likelihood for conditions like bipolar disorder, anxiety, and depression, based on polygenic risk scores (PRS).

Who are 23andMe's main partners in research?

23andMe collaborates with renowned experts and organizations, including The Michael J. Fox Foundation for Parkinson’s Research, to conduct groundbreaking studies.

What is 23andMe's vision?

23andMe aims to personalize healthcare by making meaningful discoveries through genetic research and empowering individuals with information about their genetic makeup.

What is 23ME-00610?

23ME-00610 is an anti-CD200R1 antibody developed by 23andMe, currently showing promise in Phase 2 clinical trials for its efficacy and safety in treating certain cancers.

How does 23andMe protect user data?

23andMe employs various security measures to protect user data, though the recent data breach has highlighted the need for increased vigilance and transparency.

How can customers participate in 23andMe's research?

Customers can participate in 23andMe’s research by consenting to share their genetic and health information, helping to further scientific understanding and discoveries.

Stock ME logo
23andMe Holding Co.

Nasdaq:ME

ME Rankings

#4518 Ranked by Market Cap
N/A Ranked by Dividends

ME Stock Data

82.79M
18.44M
3.65%
33.33%
3.98%
Diagnostics & Research
Pharmaceutical Preparations
Link
United States of America
SUNNYVALE